Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCSW) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for HeartSciences (HSCSW) over the last 5 years, with Q4 2025 value amounting to $2.0 million.

  • HeartSciences' Cash & Equivalents fell 5184.98% to $2.0 million in Q4 2025 from the same period last year, while for Oct 2025 it was $2.0 million, marking a year-over-year decrease of 5184.98%. This contributed to the annual value of $1.1 million for FY2025, which is 8109.22% down from last year.
  • Latest data reveals that HeartSciences reported Cash & Equivalents of $2.0 million as of Q4 2025, which was down 5184.98% from $2.8 million recorded in Q3 2025.
  • In the past 5 years, HeartSciences' Cash & Equivalents ranged from a high of $7.1 million in Q1 2024 and a low of $100144.0 during Q4 2023
  • For the 5-year period, HeartSciences' Cash & Equivalents averaged around $2.7 million, with its median value being $2.3 million (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9674.43% in 2023, then surged by 394629.33% in 2024.
  • Quarter analysis of 5 years shows HeartSciences' Cash & Equivalents stood at $723481.0 in 2021, then soared by 325.16% to $3.1 million in 2022, then plummeted by 96.74% to $100144.0 in 2023, then surged by 3946.29% to $4.1 million in 2024, then tumbled by 51.85% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q4 2025, $2.8 million for Q3 2025, and $1.1 million during Q2 2025.